• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, September 1, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

ESMO supports the 2017 WHO cancer resolution

Bioengineer by Bioengineer
February 16, 2017
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

ESMO, the leading European professional organisation for medical oncology, presented an official statement supporting the 2017 WHO Cancer Resolution that was discussed at the 140th session of the WHO Executive Board meeting in Geneva, 23-31 January 2017.

Dr Alexandru Eniu, Chair of the ESMO Global Policy Committee, declared that "ESMO supports the 2017 WHO Cancer Resolution which will improve access and affordability of cancer care and its integration into national healthcare systems: because as medical oncologists we want to assure that our patients have timely access to safe, high-quality medicines, treatment and care that are both accessible and affordable."

ESMO's statement advocates for a robust and comprehensive Cancer Resolution that can help drive national progress, particularly in low- and middle-income countries that face the biggest challenges of a rapidly growing cancer burden. The Cancer Resolution will be a landmark document for cancer and calls for the development and implementation of national cancer plans, population-based cancer registries, a world cancer report and a well-trained oncology workforce. ESMO President Fortunato Ciardiello commented: "Any kind of public health system should strongly encourage cancer prevention, diagnosis and treatment. Whatever a country can afford, health is a citizen's right and the community should try to give this right to all citizens."

An ESMO delegation of officers and senior staff attended the 140th session of the WHO Executive Board meeting, where topics relevant to the practice of medical oncology were discussed, such as access to medicines, the implementation of the current WHO Global Strategy on the Prevention and Control of Non-Communicable Diseases, the UN Sustainable Development Goals, and a Cancer Resolution. As a non-State actor in official relations with WHO, ESMO is invited to attend WHO Governing Bodies meetings and post position statements, making its views known prior and during any debate.

There was widespread agreement by Member States of the need for a 2017 WHO Cancer Resolution, which will provide specific recommendations on cancer management to complement the Global Strategy on the Prevention and Control of Non-Communicable Diseases 2013-2020. The majority of the Resolution was accepted with great support.

WHO Member States will continue to work on the final text with the goal that it can be presented for adoption at the 2017 World Health Assembly in May 2017. In the meantime, ESMO and its national partner societies worldwide will continue their dialogues with Ministries of Health to encourage as many countries as possible to vote in favour of adopting the Resolution in May.

###

Media Contact

Vanessa Pavinato
[email protected]
@myesmo

http://www.esmo.org

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

August 31, 2026
Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

August 31, 2026

KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

August 31, 2026

Virologist awarded $2 million NIH grant to investigate how virus-infected cells live and die

August 31, 2026
Please login to join discussion

POPULAR NEWS

  • β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

    29 shares
    Share 12 Tweet 7
  • Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

    29 shares
    Share 12 Tweet 7
  • KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

    29 shares
    Share 12 Tweet 7
  • Virologist awarded $2 million NIH grant to investigate how virus-infected cells live and die

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

β-Sitosterol from Ipomoea carnea Jacq. As a promising anti-inflammatory agent: Evidence from in silico modeling and in vitro validation

Design, fabrication and characterization of a wearable Fiber Bragg grating sensor for cardiorespiratory monitoring using finger plethysmography

KAIST opens the era of industrial-scale microbial foods, proposing growth strategies for the next-generation protein market

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 85 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.